Biological Activity of Peptide SCV-07 Against Murine Tuberculosis

Area of Science:

• Immunology
• Pharmacology
• Infectious Diseases

Background:

• Tuberculosis (TB) remains a significant global health challenge, necessitating novel therapeutic approaches.
• Existing treatments can have limitations, highlighting the need for adjunct therapies to enhance immune response.
• SCV-07 (gamma-glutamyl-tryptophan) is a patented immunomodulatory compound with demonstrated immunostimulatory activities.

Purpose of the Study:

• To investigate the efficacy of SCV-07 in a murine model of experimental tuberculosis (TB) induced by Mycobacterium bovis-bovinus.
• To evaluate the impact of SCV-07 on immune parameters, including cytokine production, cell proliferation, and macrophage function.
• To assess SCV-07's potential as an adjunct therapy to improve anti-TB treatment outcomes.

Main Methods:

• Mice were infected with M. bovis-bovinus 8 and treated with varying doses of SCV-07 or isoniazid.
• Lung damage index, bacterial growth in spleen cultures, and cytokine profiles (IL-2, IFN-gamma, IL-4) were assessed.
• Thymic and spleen cell proliferation, serum cytokine levels, and peritoneal macrophage phagocytosis were analyzed.

Main Results:

• SCV-07 treatment significantly decreased lung damage and M. bovis-bovinus growth in spleen cultures compared to controls and isoniazid alone.
• SCV-07 restored IL-2 production and T-cell proliferative responses to levels seen in uninfected animals.
• Treatment increased IFN-gamma and decreased IL-4 production, indicating a shift towards a Th1 immune response, and enhanced macrophage phagocytosis.

Conclusions:

• SCV-07 demonstrates potent immunomodulatory effects in a murine TB model, shifting the immune response towards a Th1 profile.
• The compound improved macrophage function and enhanced the efficacy of anti-tuberculosis therapy.
• SCV-07 is a promising candidate for inclusion in complex therapeutic strategies for TB.